Home

Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB)

3.1900
-0.0500 (-1.54%)
NASDAQ · Last Trade: Jul 25th, 9:52 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
On Thursday, there are stocks with unusual volume. Let's take a look.chartmill.com
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via Chartmill · July 24, 2025
Crude Oil Falls; Thermo Fisher Scientific Earnings Top Viewsbenzinga.com
Via Benzinga · July 23, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · July 23, 2025
Dow Surges Over 200 Points; AT&T Posts Upbeat Earningsbenzinga.com
Via Benzinga · July 23, 2025
Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Saysbenzinga.com
H.C.
Via Benzinga · September 18, 2023
Anebulo Pharmaceuticals: Q3 Earnings Insightsbenzinga.com
Via Benzinga · May 11, 2023
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · July 23, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · March 27, 2025
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · March 13, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 26, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 24, 2024
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga.com
Via Benzinga · June 7, 2024
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga.com
Via Benzinga · May 31, 2024
ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024investorplace.com
ANEB stock results show that Anebulo Pharmaceuticals beat analyst estimates for earnings per share the third quarter of 2024.
Via InvestorPlace · May 15, 2024
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drugbenzinga.com
Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday second quarter financial results for the three months ended Dec. 31, 2023, The company's primary focus is on developing therapy for acute cannabinoid intoxication (ACI).Total operating expenses in the second quarter of fiscal 2024 were $2.8 million compared with $3.8 million in the same period in fiscal 2023.Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.
Via Benzinga · February 14, 2024
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · December 21, 2023
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
Via Benzinga · October 17, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · October 17, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023benzinga.com
Via Benzinga · September 18, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · August 22, 2023
Anebulo Receives Positive Feedback From FDA On Path To Phase 3 Trial Of Its Drug For Acute Cannabinoid Intoxicationbenzinga.com
Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced positive feedback from the United States Food and Drug Administration following a type B meeting in July.
Via Benzinga · August 21, 2023
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · August 21, 2023
Antidote For THC? Anebulo Releases Positive Clinical Data Showing Potential Of Its Drug For Treatment Of Acute Cannabinoid Intoxicationbenzinga.com
Anebulo Pharmaceuticals, Inc.
Via Benzinga · March 29, 2023
Latest Executive Changes In Marijuana Industry, New Appointments & Resignationsbenzinga.com
As the Benzinga Cannabis Capital Conference returns to Miami (April 11-12), gathering top CEOs, investors and leaders in the mari
Via Benzinga · March 13, 2023
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the European market.
Via Benzinga · March 7, 2023